JP2008515962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515962A5 JP2008515962A5 JP2007536276A JP2007536276A JP2008515962A5 JP 2008515962 A5 JP2008515962 A5 JP 2008515962A5 JP 2007536276 A JP2007536276 A JP 2007536276A JP 2007536276 A JP2007536276 A JP 2007536276A JP 2008515962 A5 JP2008515962 A5 JP 2008515962A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- ylmethyl
- acetyl
- boc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- -1 nitro, hydroxy Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 8
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 150000002825 nitriles Chemical class 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 claims 3
- QGNOGAFKDGNVQA-FQUUOJAGSA-N (2s,4s)-1-[2-[[(1r,3r)-3-(2-cyanoethyl)cyclopentyl]amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CCC#N)CC1 QGNOGAFKDGNVQA-FQUUOJAGSA-N 0.000 claims 2
- YMXGFRQHFHFPOW-XQHKEYJVSA-N (2s,4s)-1-[2-[[(1r,3s)-3-(cyanomethyl)cyclopentyl]amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CC#N)CC1 YMXGFRQHFHFPOW-XQHKEYJVSA-N 0.000 claims 2
- YMXGFRQHFHFPOW-CYDGBPFRSA-N (2s,4s)-1-[2-[[(1s,3r)-3-(cyanomethyl)cyclopentyl]amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@@H]1C[C@H](CC#N)CC1 YMXGFRQHFHFPOW-CYDGBPFRSA-N 0.000 claims 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 239000005973 Carvone Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Natural products CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims 2
- 150000001753 carvones Chemical class 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- JSXSIVQMYRIDBD-SBKWZQTDSA-N (1R,3S)-3-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)cyclopentan-1-amine 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.C1N(CCC2=CC=CC=C12)C[C@@H]1C[C@@H](CC1)N JSXSIVQMYRIDBD-SBKWZQTDSA-N 0.000 claims 1
- FISJYXZOMFAWTH-SCLLHFNJSA-N (1r,3r)-3-(1,2,4-triazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@H]1CN1N=CN=C1 FISJYXZOMFAWTH-SCLLHFNJSA-N 0.000 claims 1
- ZMBNLBSFOOZHKQ-MHDYBILJSA-N (1r,3r)-3-[(2-methoxyphenyl)methyl]cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC=C1C[C@@H]1C[C@H](N)CC1 ZMBNLBSFOOZHKQ-MHDYBILJSA-N 0.000 claims 1
- XYBQISJWMAKZSH-VXGBXAGGSA-N (1r,3r)-3-benzylcyclopentan-1-amine Chemical compound C1[C@H](N)CC[C@@H]1CC1=CC=CC=C1 XYBQISJWMAKZSH-VXGBXAGGSA-N 0.000 claims 1
- FISJYXZOMFAWTH-KZYPOYLOSA-N (1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1N=CN=C1 FISJYXZOMFAWTH-KZYPOYLOSA-N 0.000 claims 1
- ATXGSMDSURIOLC-YECZQDJWSA-N (1r,3s)-3-(1,3-dihydroisoindol-2-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1CC2=CC=CC=C2C1 ATXGSMDSURIOLC-YECZQDJWSA-N 0.000 claims 1
- YHGHGAYGONPKEX-BAUSSPIASA-N (1r,3s)-3-(2,3-dihydrobenzotriazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1C2=CC=CC=C2NN1 YHGHGAYGONPKEX-BAUSSPIASA-N 0.000 claims 1
- RFTDZQBDJJRODQ-STEACBGWSA-N (1r,3s)-3-(2,3-dihydroindol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1C2=CC=CC=C2CC1 RFTDZQBDJJRODQ-STEACBGWSA-N 0.000 claims 1
- LZHZTLXNTKYUOH-VHSXEESVSA-N (1r,3s)-3-(benzotriazol-2-ylmethyl)cyclopentan-1-amine Chemical compound C1[C@H](N)CC[C@@H]1CN1N=C2C=CC=CC2=N1 LZHZTLXNTKYUOH-VHSXEESVSA-N 0.000 claims 1
- HRRLDCXWMGNJIP-BAUSSPIASA-N (1r,3s)-3-(benzotriazol-2-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1N=C2C=CC=CC2=N1 HRRLDCXWMGNJIP-BAUSSPIASA-N 0.000 claims 1
- PGFKSJGKEMYPAV-OULXEKPRSA-N (1r,3s)-3-(imidazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1C=NC=C1 PGFKSJGKEMYPAV-OULXEKPRSA-N 0.000 claims 1
- RDIMQQQRELYIMA-BAUSSPIASA-N (1r,3s)-3-(morpholin-4-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1CCOCC1 RDIMQQQRELYIMA-BAUSSPIASA-N 0.000 claims 1
- FUVZLVBWGATPDZ-OULXEKPRSA-N (1r,3s)-3-[(1,1-dioxo-1,2-thiazolidin-2-yl)methyl]cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1S(=O)(=O)CCC1 FUVZLVBWGATPDZ-OULXEKPRSA-N 0.000 claims 1
- GHPBFIPVTAHUFH-ZVWHLABXSA-N (1r,3s)-3-[(2,5-dimethylpyrrol-1-yl)methyl]cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=C(C)N1C[C@@H]1C[C@H](N)CC1 GHPBFIPVTAHUFH-ZVWHLABXSA-N 0.000 claims 1
- FISJYXZOMFAWTH-WLYNEOFISA-N (1s,3r)-3-(1,2,4-triazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@@H](N)CC[C@H]1CN1N=CN=C1 FISJYXZOMFAWTH-WLYNEOFISA-N 0.000 claims 1
- HARICIXQCOMWDS-IYJPBCIQSA-N (1s,3r)-3-(indazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@@H](N)CC[C@H]1CN1C2=CC=CC=C2C=N1 HARICIXQCOMWDS-IYJPBCIQSA-N 0.000 claims 1
- SOGGGKAUCJMOPN-IYJPBCIQSA-N (1s,3r)-3-(indazol-2-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@@H](N)CC[C@H]1CN1N=C2C=CC=CC2=C1 SOGGGKAUCJMOPN-IYJPBCIQSA-N 0.000 claims 1
- YMXLUFVZWKQJKJ-RJUBDTSPSA-N (1s,3r)-3-(pyrazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@@H](N)CC[C@H]1CN1N=CC=C1 YMXLUFVZWKQJKJ-RJUBDTSPSA-N 0.000 claims 1
- GTEVGUPANVPJRC-WLYNEOFISA-N (1s,3r)-3-(triazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@@H](N)CC[C@H]1CN1N=NC=C1 GTEVGUPANVPJRC-WLYNEOFISA-N 0.000 claims 1
- VROJAWMOYZWSNX-WLYNEOFISA-N (1s,3r)-3-(triazol-2-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@@H](N)CC[C@H]1CN1N=CC=N1 VROJAWMOYZWSNX-WLYNEOFISA-N 0.000 claims 1
- CRCFMMTVWUXGKH-LIOBNPLQSA-N (1s,3r)-3-[(4-phenylpiperazin-1-yl)methyl]cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@@H](N)CC[C@H]1CN1CCN(C=2C=CC=CC=2)CC1 CRCFMMTVWUXGKH-LIOBNPLQSA-N 0.000 claims 1
- MUMSEHFWBGQGNG-KZYPOYLOSA-N (1s,4r)-4-(1,2,4-triazol-1-ylmethyl)cyclopent-2-en-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C[C@@H](N)C[C@H]1CN1N=CN=C1 MUMSEHFWBGQGNG-KZYPOYLOSA-N 0.000 claims 1
- JJCWCECVSFPLRC-IMUQEULPSA-N (2s)-1-(3-aminocyclopentanecarbonyl)pyrrolidine-2-carbonitrile;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1C(N)CCC1C(=O)N1[C@H](C#N)CCC1 JJCWCECVSFPLRC-IMUQEULPSA-N 0.000 claims 1
- OPBAUWWPQFSAOI-MCIGGMRASA-N (2s)-1-[2-[(3-cyanocyclopentyl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC1CCC(C#N)C1 OPBAUWWPQFSAOI-MCIGGMRASA-N 0.000 claims 1
- NZHRKBKTKWQHRW-MJBXVCDLSA-N (2s)-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@H]1CC[C@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1C=NC=N1 NZHRKBKTKWQHRW-MJBXVCDLSA-N 0.000 claims 1
- PPGDORKIIFXPNU-DBVUQKKJSA-N (2s)-1-[2-[[(1r,3s)-3-(1,3-dihydroisoindol-2-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@H]1C[C@@H](CN2CC3=CC=CC=C3C2)CC1)CC(=O)N1CCC[C@H]1C#N PPGDORKIIFXPNU-DBVUQKKJSA-N 0.000 claims 1
- NWOQBZHQGOHVFO-XHSDSOJGSA-N (2s)-1-[2-[[(1r,3s)-3-(2,3-dihydrobenzotriazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@H]1C[C@@H](CN2C3=CC=CC=C3NN2)CC1)CC(=O)N1CCC[C@H]1C#N NWOQBZHQGOHVFO-XHSDSOJGSA-N 0.000 claims 1
- MVTWTTDMTPSOJY-UHOSZYNNSA-N (2s)-1-[2-[[(1r,3s)-3-(2,3-dihydroindol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@H]1C[C@@H](CN2C3=CC=CC=C3CC2)CC1)CC(=O)N1CCC[C@H]1C#N MVTWTTDMTPSOJY-UHOSZYNNSA-N 0.000 claims 1
- MTNUXJUPIJQLHH-BBWFWOEESA-N (2s)-1-[2-[[(1r,3s)-3-(benzimidazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@H]1C[C@@H](CN2C3=CC=CC=C3N=C2)CC1)CC(=O)N1CCC[C@H]1C#N MTNUXJUPIJQLHH-BBWFWOEESA-N 0.000 claims 1
- VMYUSJJAIOYGFX-XHSDSOJGSA-N (2s)-1-[2-[[(1r,3s)-3-(benzotriazol-2-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@H]1C[C@@H](CN2N=C3C=CC=CC3=N2)CC1)CC(=O)N1CCC[C@H]1C#N VMYUSJJAIOYGFX-XHSDSOJGSA-N 0.000 claims 1
- NGZTVZNWLPPVGQ-UPJWGTAASA-N (2s)-1-[2-[[(1r,3s)-3-(cyanomethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CN[C@@H]1CC[C@H](CC#N)C1 NGZTVZNWLPPVGQ-UPJWGTAASA-N 0.000 claims 1
- WTSADRPXCPMCAW-ZNMIVQPWSA-N (2s)-1-[2-[[(1r,3s)-3-(imidazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@H]1CC[C@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1C=CN=C1 WTSADRPXCPMCAW-ZNMIVQPWSA-N 0.000 claims 1
- KIHLKFPJLZFBGT-XHSDSOJGSA-N (2s)-1-[2-[[(1r,3s)-3-(morpholin-4-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@H]1CC[C@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1CCOCC1 KIHLKFPJLZFBGT-XHSDSOJGSA-N 0.000 claims 1
- KLOWNBULXQPQHF-ZNMIVQPWSA-N (2s)-1-[2-[[(1r,3s)-3-[(1,1-dioxo-1,2-thiazolidin-2-yl)methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@H]1CC[C@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1CCCS1(=O)=O KLOWNBULXQPQHF-ZNMIVQPWSA-N 0.000 claims 1
- YMTDMNKORGPJSB-QGTPRVQTSA-N (2s)-1-[2-[[(1r,3s)-3-[[5-(4-fluorophenyl)tetrazol-2-yl]methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1=CC(F)=CC=C1C1=NN(C[C@@H]2C[C@@H](CC2)NCC(=O)N2[C@@H](CCC2)C#N)N=N1 YMTDMNKORGPJSB-QGTPRVQTSA-N 0.000 claims 1
- NZHRKBKTKWQHRW-RDBSUJKOSA-N (2s)-1-[2-[[(1s,3r)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1CC[C@@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1C=NC=N1 NZHRKBKTKWQHRW-RDBSUJKOSA-N 0.000 claims 1
- NGZTVZNWLPPVGQ-AVGNSLFASA-N (2s)-1-[2-[[(1s,3r)-3-(cyanomethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CN[C@H]1CC[C@@H](CC#N)C1 NGZTVZNWLPPVGQ-AVGNSLFASA-N 0.000 claims 1
- SJHWGKPRJMQRHX-NJAFHUGGSA-N (2s)-1-[2-[[(1s,3r)-3-(indazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@@H]1C[C@H](CN2C3=CC=CC=C3C=N2)CC1)CC(=O)N1CCC[C@H]1C#N SJHWGKPRJMQRHX-NJAFHUGGSA-N 0.000 claims 1
- NOOBGDIVBHZHAJ-NJAFHUGGSA-N (2s)-1-[2-[[(1s,3r)-3-(indazol-2-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@@H]1C[C@H](CN2N=C3C=CC=CC3=C2)CC1)CC(=O)N1CCC[C@H]1C#N NOOBGDIVBHZHAJ-NJAFHUGGSA-N 0.000 claims 1
- QGNRKZMCGJBYSD-ILXRZTDVSA-N (2s)-1-[2-[[(1s,3r)-3-(pyrazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1CC[C@@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1C=CC=N1 QGNRKZMCGJBYSD-ILXRZTDVSA-N 0.000 claims 1
- BRPQMFNSYFZPLR-RDBSUJKOSA-N (2s)-1-[2-[[(1s,3r)-3-(triazol-2-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1CC[C@@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1N=CC=N1 BRPQMFNSYFZPLR-RDBSUJKOSA-N 0.000 claims 1
- HQDWBFMTDPWUFE-URVUXULASA-N (2s)-1-[2-[[(1s,3r)-3-[(4-phenylpiperazin-1-yl)methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1CC[C@@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N(CC1)CCN1C1=CC=CC=C1 HQDWBFMTDPWUFE-URVUXULASA-N 0.000 claims 1
- NZHRKBKTKWQHRW-RUXDESIVSA-N (2s)-1-[2-[[3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CCC1CN1C=NC=N1 NZHRKBKTKWQHRW-RUXDESIVSA-N 0.000 claims 1
- NICVLZBRCPWCAC-NRXISQOPSA-N (2s)-1-[2-[[3-(1,3-thiazolidin-3-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CCC1CN1CCSC1 NICVLZBRCPWCAC-NRXISQOPSA-N 0.000 claims 1
- NGZTVZNWLPPVGQ-BPCQOVAHSA-N (2s)-1-[2-[[3-(cyanomethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC1CCC(CC#N)C1 NGZTVZNWLPPVGQ-BPCQOVAHSA-N 0.000 claims 1
- YKQBPZCZJJHCEZ-VNXZQDSDSA-N (2s)-1-[2-[[3-[(4-benzylpiperazin-1-yl)methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CCC1CN(CC1)CCN1CC1=CC=CC=C1 YKQBPZCZJJHCEZ-VNXZQDSDSA-N 0.000 claims 1
- QULDJKFBPRFVJU-JCYILVPMSA-N (2s)-1-[2-[[3-[(4-methylpiperazin-1-yl)methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CN(C)CCN1CC1CC(NCC(=O)N2[C@@H](CCC2)C#N)CC1 QULDJKFBPRFVJU-JCYILVPMSA-N 0.000 claims 1
- UUACHWJZZYHNDN-JCYILVPMSA-N (2s)-1-[2-[[3-[[2-butyl-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1CC(NCC(=O)N2[C@@H](CCC2)C#N)CC1 UUACHWJZZYHNDN-JCYILVPMSA-N 0.000 claims 1
- CUCMMYSRHBDPSP-XDNAFOTISA-N (2s,4s)-1-[2-[[(1r,3r)-3-benzylcyclopentyl]amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CC=2C=CC=CC=2)CC1 CUCMMYSRHBDPSP-XDNAFOTISA-N 0.000 claims 1
- UUCQSOXCUYPYQY-DVWBAYGPSA-N (2s,4s)-1-[2-[[(1r,3s)-3-(3,4-dihydro-1h-isoquinolin-2-ylmethyl)cyclopentyl]amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2CC3=CC=CC=C3CC2)CC1 UUCQSOXCUYPYQY-DVWBAYGPSA-N 0.000 claims 1
- JSYGLDMGERSRPC-RQJABVFESA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3r)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-RQJABVFESA-N 0.000 claims 1
- JSYGLDMGERSRPC-FQUUOJAGSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-FQUUOJAGSA-N 0.000 claims 1
- POHFRNVKGQVFQA-QVYXHAGSSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 POHFRNVKGQVFQA-QVYXHAGSSA-N 0.000 claims 1
- IRNUBPKZFZIPQB-QVYXHAGSSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 IRNUBPKZFZIPQB-QVYXHAGSSA-N 0.000 claims 1
- STCKGUTYUCRBAW-QVYXHAGSSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 STCKGUTYUCRBAW-QVYXHAGSSA-N 0.000 claims 1
- IAWFHPXSNMKWIL-QVYXHAGSSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 IAWFHPXSNMKWIL-QVYXHAGSSA-N 0.000 claims 1
- CUPYARVFYSBASZ-QVYXHAGSSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 CUPYARVFYSBASZ-QVYXHAGSSA-N 0.000 claims 1
- JSYGLDMGERSRPC-RFGFWPKPSA-N (2s,4s)-4-fluoro-1-[2-[[(1s,3r)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@@H]1C[C@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-RFGFWPKPSA-N 0.000 claims 1
- XFYHCMFFNFVTDO-RFGFWPKPSA-N (2s,4s)-4-fluoro-1-[2-[[(1s,3r)-3-(triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@@H]1C[C@H](CN2N=NC=C2)CC1 XFYHCMFFNFVTDO-RFGFWPKPSA-N 0.000 claims 1
- PIAHSBFVAGEXGC-RFGFWPKPSA-N (2s,4s)-4-fluoro-1-[2-[[(1s,3r)-3-(triazol-2-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@@H]1C[C@H](CN2N=CC=N2)CC1 PIAHSBFVAGEXGC-RFGFWPKPSA-N 0.000 claims 1
- JSYGLDMGERSRPC-YIOUJQMASA-N (2s,4s)-4-fluoro-1-[2-[[3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CNC1CC(CN2N=CN=C2)CC1 JSYGLDMGERSRPC-YIOUJQMASA-N 0.000 claims 1
- HNPOHJCNUGAMBX-XQQFMLRXSA-N (4s)-3-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]-1,3-thiazolidine-4-carbonitrile Chemical compound C([C@H]1CC[C@H](C1)NCC(=O)N1[C@H](CSC1)C#N)N1C=NC=N1 HNPOHJCNUGAMBX-XQQFMLRXSA-N 0.000 claims 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims 1
- KHEUMASIBMHVDN-UHFFFAOYSA-N 1-[(3-aminocyclopentyl)methyl]imidazole-4,5-dicarbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCC1CN1C(C#N)=C(C#N)N=C1 KHEUMASIBMHVDN-UHFFFAOYSA-N 0.000 claims 1
- HOOWPWJEZJUOMS-UHFFFAOYSA-N 1-[(3-aminocyclopentyl)methyl]piperidine-4-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCC1CN1CCC(C#N)CC1 HOOWPWJEZJUOMS-UHFFFAOYSA-N 0.000 claims 1
- KDPZYROJJJPHHO-UHFFFAOYSA-N 1-[(3-aminocyclopentyl)methyl]pyrrole-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCC1CN1C(C#N)=CC=C1 KDPZYROJJJPHHO-UHFFFAOYSA-N 0.000 claims 1
- UGINQCSZZAQRFU-AVGNSLFASA-N 1-[(3s)-3-fluoropyrrolidin-1-yl]-2-[[(1s,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]ethanone Chemical compound C1[C@@H](F)CCN1C(=O)CN[C@@H]1C[C@@H](CN2N=CN=C2)CC1 UGINQCSZZAQRFU-AVGNSLFASA-N 0.000 claims 1
- NZHRKBKTKWQHRW-UHFFFAOYSA-N 1-[2-[[3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CCC(C#N)N1C(=O)CNC(C1)CCC1CN1C=NC=N1 NZHRKBKTKWQHRW-UHFFFAOYSA-N 0.000 claims 1
- DZAUDFPNCPWWHR-UHFFFAOYSA-N 1-[2-[[3-(tetrazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CCC(C#N)N1C(=O)CNC(C1)CCC1CN1C=NN=N1 DZAUDFPNCPWWHR-UHFFFAOYSA-N 0.000 claims 1
- NLKFAEPQTPGBGC-IMJJTQAJSA-N 1-[[(1s,3r)-3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]-3-(2,4-difluorophenyl)urea Chemical compound FC1=CC(F)=CC=C1NC(=O)NC[C@@H]1C[C@H](NCC(=O)N2[C@@H](CCC2)C#N)CC1 NLKFAEPQTPGBGC-IMJJTQAJSA-N 0.000 claims 1
- FYUYSZWTRRMUHA-JQHSSLGASA-N 1-[[(1s,3r)-3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]-3-phenylurea Chemical compound N([C@@H]1CC[C@@H](C1)CNC(=O)NC=1C=CC=CC=1)CC(=O)N1CCC[C@H]1C#N FYUYSZWTRRMUHA-JQHSSLGASA-N 0.000 claims 1
- QPAMGHDYOHMUTC-ZNMIVQPWSA-N 1-[[(1s,3r)-3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]imidazole-4,5-dicarbonitrile Chemical compound C([C@H]1CC[C@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1C=NC(C#N)=C1C#N QPAMGHDYOHMUTC-ZNMIVQPWSA-N 0.000 claims 1
- MSXKKBCRWHYGSD-UXLLHSPISA-N 1-[[(1s,3r)-3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]pyrrole-2-carbonitrile Chemical compound C([C@H]1CC[C@H](C1)NCC(=O)N1[C@@H](CCC1)C#N)N1C=CC=C1C#N MSXKKBCRWHYGSD-UXLLHSPISA-N 0.000 claims 1
- AIEZEOTXDJJYSZ-KANFNMMFSA-N 1-[[(1s,3r)-3-[[2-[(2s,4s)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]indole-3-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2C3=CC=CC=C3C(C#N)=C2)CC1 AIEZEOTXDJJYSZ-KANFNMMFSA-N 0.000 claims 1
- MFQSMHFDLYFEAV-WDEREUQCSA-N 1-[[(1s,3r)-3-aminocyclopentyl]methyl]-3-phenylurea Chemical compound C1[C@H](N)CC[C@@H]1CNC(=O)NC1=CC=CC=C1 MFQSMHFDLYFEAV-WDEREUQCSA-N 0.000 claims 1
- KHEUMASIBMHVDN-OULXEKPRSA-N 1-[[(1s,3r)-3-aminocyclopentyl]methyl]imidazole-4,5-dicarbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1C(C#N)=C(C#N)N=C1 KHEUMASIBMHVDN-OULXEKPRSA-N 0.000 claims 1
- JLUKTMYEFPKBIT-STEACBGWSA-N 1-[[(1s,3r)-3-aminocyclopentyl]methyl]indole-3-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1C2=CC=CC=C2C(C#N)=C1 JLUKTMYEFPKBIT-STEACBGWSA-N 0.000 claims 1
- KDPZYROJJJPHHO-BAUSSPIASA-N 1-[[(1s,3r)-3-aminocyclopentyl]methyl]pyrrole-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1[C@H](N)CC[C@@H]1CN1C(C#N)=CC=C1 KDPZYROJJJPHHO-BAUSSPIASA-N 0.000 claims 1
- QPAMGHDYOHMUTC-NRXISQOPSA-N 1-[[3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]imidazole-4,5-dicarbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CCC1CN1C=NC(C#N)=C1C#N QPAMGHDYOHMUTC-NRXISQOPSA-N 0.000 claims 1
- VOWUTEFBRHOLNE-ABHNRTSZSA-N 1-[[3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]piperidine-4-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CCC1CN1CCC(C#N)CC1 VOWUTEFBRHOLNE-ABHNRTSZSA-N 0.000 claims 1
- LXVNGBWXZCVENM-UHFFFAOYSA-N 2-(3-aminocyclopentyl)acetonitrile 4-methylbenzenesulfonic acid Chemical compound C1(=CC=C(C=C1)S(=O)(=O)O)C.NC1CC(CC1)CC#N LXVNGBWXZCVENM-UHFFFAOYSA-N 0.000 claims 1
- KNBZXIPHHDLWSZ-ZJLYAJKPSA-N 2-[(1s,3r)-3-aminocyclopentyl]acetonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N[C@@H]1CC[C@H](CC#N)C1 KNBZXIPHHDLWSZ-ZJLYAJKPSA-N 0.000 claims 1
- LXVNGBWXZCVENM-ZJLYAJKPSA-N 2-[(1s,3r)-3-aminocyclopentyl]acetonitrile;4-methylbenzenesulfonic acid Chemical compound N[C@@H]1CC[C@H](CC#N)C1.CC1=CC=C(S(O)(=O)=O)C=C1 LXVNGBWXZCVENM-ZJLYAJKPSA-N 0.000 claims 1
- OHCQGILMLJDBSB-JCYILVPMSA-N 2-butyl-5-chloro-3-[[3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]cyclopentyl]methyl]imidazole-4-carbonitrile Chemical compound CCCCC1=NC(Cl)=C(C#N)N1CC1CC(NCC(=O)N2[C@@H](CCC2)C#N)CC1 OHCQGILMLJDBSB-JCYILVPMSA-N 0.000 claims 1
- FISJYXZOMFAWTH-UHFFFAOYSA-N 3-(1,2,4-triazol-1-ylmethyl)cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N)CCC1CN1N=CN=C1 FISJYXZOMFAWTH-UHFFFAOYSA-N 0.000 claims 1
- GHZMPORZABIBMD-KZYPOYLOSA-N 3-[(1r,3r)-3-aminocyclopentyl]propanenitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N[C@@H]1CC[C@H](CCC#N)C1 GHZMPORZABIBMD-KZYPOYLOSA-N 0.000 claims 1
- DHUZWMGRPANQHI-UHFFFAOYSA-N 3-[(3-aminocyclopentyl)methyl]-2-butyl-5-chloroimidazole-4-carbonitrile 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCC1=NC(Cl)=C(C#N)N1CC1CC(N)CC1 DHUZWMGRPANQHI-UHFFFAOYSA-N 0.000 claims 1
- ZSBKHZFWDKWTIW-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]cyclopentan-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CN(C)CCN1CC1CC(N)CC1 ZSBKHZFWDKWTIW-UHFFFAOYSA-N 0.000 claims 1
- WLXMXNNAGLHKBM-ABHNRTSZSA-N 3-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-n-phenylmethoxycyclopentane-1-carboxamide Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CCC1C(=O)NOCC1=CC=CC=C1 WLXMXNNAGLHKBM-ABHNRTSZSA-N 0.000 claims 1
- CYDUDMFLIJSSEZ-UHFFFAOYSA-N 3-amino-N-phenylmethoxycyclopentane-1-carboxamide Chemical compound C1C(N)CCC1C(=O)NOCC1=CC=CC=C1 CYDUDMFLIJSSEZ-UHFFFAOYSA-N 0.000 claims 1
- YGLATEGGVDJYJL-UHFFFAOYSA-N 3-aminocyclopentane-1-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC1CCC(C#N)C1 YGLATEGGVDJYJL-UHFFFAOYSA-N 0.000 claims 1
- TVDDQMZZEVWYOR-UHFFFAOYSA-N 3-aminocyclopentane-1-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC1CCC(C(N)=O)C1 TVDDQMZZEVWYOR-UHFFFAOYSA-N 0.000 claims 1
- JSYGLDMGERSRPC-UHFFFAOYSA-N 4-fluoro-1-[2-[[3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1C(F)CC(C#N)N1C(=O)CNC1CC(CN2N=CN=C2)CC1 JSYGLDMGERSRPC-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- ORSWHUYJTRPPGH-MLHJIOFPSA-N CC=1N(C(=CC1)C)C[C@@H]1C[C@@H](CC1)NCC(=O)N1[C@@H](C[C@H](C1)F)C#N Chemical compound CC=1N(C(=CC1)C)C[C@@H]1C[C@@H](CC1)NCC(=O)N1[C@@H](C[C@H](C1)F)C#N ORSWHUYJTRPPGH-MLHJIOFPSA-N 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- XGTQCNRTYRCCPJ-UHFFFAOYSA-N OC(=O)C(F)(F)F.NC1CCC(CN2CCN(Cc3ccccc3)CC2)C1 Chemical compound OC(=O)C(F)(F)F.NC1CCC(CN2CCN(Cc3ccccc3)CC2)C1 XGTQCNRTYRCCPJ-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- JCHKOCXNRPPLPN-UHFFFAOYSA-N [3-[(3-aminocyclopentyl)methyl]-2-butyl-5-chloroimidazol-4-yl]methanol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCC1=NC(Cl)=C(CO)N1CC1CC(N)CC1 JCHKOCXNRPPLPN-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- MLFNHWPTYYDHNX-QVYXHAGSSA-N benzenesulfonic acid;(2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 MLFNHWPTYYDHNX-QVYXHAGSSA-N 0.000 claims 1
- VEWGCCUCYRZXGD-QVYXHAGSSA-N benzoic acid;(2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OC(=O)C1=CC=CC=C1.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 VEWGCCUCYRZXGD-QVYXHAGSSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- PDCOUWWHMGZMHD-QVYXHAGSSA-N butanedioic acid;(2s,4s)-4-fluoro-1-[2-[[(1r,3s)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OC(=O)CCC(O)=O.C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 PDCOUWWHMGZMHD-QVYXHAGSSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- QLBQHUZGRRAMIW-UHFFFAOYSA-N tert-butyl 2-[(3-aminocyclopentyl)methyl]-4-cyanopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#N)CC1CC1CC(N)CC1 QLBQHUZGRRAMIW-UHFFFAOYSA-N 0.000 claims 1
- SQFJKYHIYHWTDW-WDEREUQCSA-N tert-butyl 2-[[(1s,3r)-3-aminocyclopentyl]methyl]imidazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CN=C1C[C@@H]1C[C@H](N)CC1 SQFJKYHIYHWTDW-WDEREUQCSA-N 0.000 claims 1
- DODGKPFEEHFIFC-SWLSCSKDSA-N tert-butyl 3-[[(1s,3r)-3-aminocyclopentyl]methyl]-5-(4-fluorophenyl)-2h-tetrazole-4-carboxylate Chemical compound N1N=C(C=2C=CC(F)=CC=2)N(C(=O)OC(C)(C)C)N1C[C@H]1CC[C@@H](N)C1 DODGKPFEEHFIFC-SWLSCSKDSA-N 0.000 claims 1
- NURPNHACIAZBQN-GHMZBOCLSA-N tert-butyl n-[(1r,3r)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CC[C@H]1CN1N=CN=C1 NURPNHACIAZBQN-GHMZBOCLSA-N 0.000 claims 1
- PYRRDBYJYOSIPM-UKRRQHHQSA-N tert-butyl n-[(1r,3r)-3-[(2-methoxyphenyl)methyl]cyclopentyl]carbamate Chemical compound COC1=CC=CC=C1C[C@@H]1C[C@H](NC(=O)OC(C)(C)C)CC1 PYRRDBYJYOSIPM-UKRRQHHQSA-N 0.000 claims 1
- YOXJTUIOYALYHG-HUUCEWRRSA-N tert-butyl n-[(1r,3r)-3-benzylcyclopentyl]carbamate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CC[C@@H]1CC1=CC=CC=C1 YOXJTUIOYALYHG-HUUCEWRRSA-N 0.000 claims 1
- ZCZBUFNTHHYFEM-WMLDXEAASA-N tert-butyl n-[(1r,3s)-3-(1,3-dihydroisoindol-2-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CC[C@@H]1CN1CC2=CC=CC=C2C1 ZCZBUFNTHHYFEM-WMLDXEAASA-N 0.000 claims 1
- JRYWPSFBBYTGRN-GOEBONIOSA-N tert-butyl n-[(1r,3s)-3-(2,3-dihydroindol-1-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CC[C@@H]1CN1C2=CC=CC=C2CC1 JRYWPSFBBYTGRN-GOEBONIOSA-N 0.000 claims 1
- CDIKDDHRCLOSOX-MAUKXSAKSA-N tert-butyl n-[(1r,3s)-3-(3,4-dihydro-1h-isoquinolin-2-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CC[C@@H]1CN1CC2=CC=CC=C2CC1 CDIKDDHRCLOSOX-MAUKXSAKSA-N 0.000 claims 1
- VBVOOTWLGCSWQY-HIFRSBDPSA-N tert-butyl n-[(1s,3r)-3-(indazol-1-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CC[C@H]1CN1C2=CC=CC=C2C=N1 VBVOOTWLGCSWQY-HIFRSBDPSA-N 0.000 claims 1
- YGPXFIGOXNKFSP-HIFRSBDPSA-N tert-butyl n-[(1s,3r)-3-(indazol-2-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CC[C@H]1CN1N=C2C=CC=CC2=C1 YGPXFIGOXNKFSP-HIFRSBDPSA-N 0.000 claims 1
- UFKKBPOMWYMQAX-NEPJUHHUSA-N tert-butyl n-[(1s,3r)-3-(pyrazol-1-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CC[C@H]1CN1N=CC=C1 UFKKBPOMWYMQAX-NEPJUHHUSA-N 0.000 claims 1
- SNMVQJBSFAOUSL-MNOVXSKESA-N tert-butyl n-[(1s,3r)-3-(triazol-1-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CC[C@H]1CN1N=NC=C1 SNMVQJBSFAOUSL-MNOVXSKESA-N 0.000 claims 1
- SCPORULAIMGNDJ-MNOVXSKESA-N tert-butyl n-[(1s,3r)-3-(triazol-2-ylmethyl)cyclopentyl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CC[C@H]1CN1N=CC=N1 SCPORULAIMGNDJ-MNOVXSKESA-N 0.000 claims 1
- MCAQYCJCJFBDAE-MSOLQXFVSA-N tert-butyl n-[(1s,3r)-3-[(4-phenylpiperazin-1-yl)methyl]cyclopentyl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CC[C@H]1CN1CCN(C=2C=CC=CC=2)CC1 MCAQYCJCJFBDAE-MSOLQXFVSA-N 0.000 claims 1
- FTHSVVZIFSSENA-WDEREUQCSA-N tert-butyl n-[(1s,4r)-4-(1,2,4-triazol-1-ylmethyl)cyclopent-2-en-1-yl]carbamate Chemical compound C1=C[C@@H](NC(=O)OC(C)(C)C)C[C@H]1CN1N=CN=C1 FTHSVVZIFSSENA-WDEREUQCSA-N 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 0 **C1CC(*)CC1 Chemical compound **C1CC(*)CC1 0.000 description 2
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61810204P | 2004-10-12 | 2004-10-12 | |
| US60/618,102 | 2004-10-12 | ||
| IN1096/MUM/2004 | 2004-10-14 | ||
| IN1096MU2004 | 2004-10-14 | ||
| US63526604P | 2004-12-10 | 2004-12-10 | |
| US60/635,266 | 2004-12-10 | ||
| IN1332MU2004 | 2004-12-14 | ||
| IN1332/MUM/2004 | 2004-12-14 | ||
| PCT/IB2005/002204 WO2006040625A1 (en) | 2004-10-12 | 2005-07-26 | Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008515962A JP2008515962A (ja) | 2008-05-15 |
| JP2008515962A5 true JP2008515962A5 (https=) | 2008-09-11 |
| JP4959569B2 JP4959569B2 (ja) | 2012-06-27 |
Family
ID=35311627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536276A Expired - Fee Related JP4959569B2 (ja) | 2004-10-12 | 2005-07-26 | 新規なジペプチジルペプチダーゼｉｖ阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7205323B2 (https=) |
| EP (1) | EP1799639B1 (https=) |
| JP (1) | JP4959569B2 (https=) |
| KR (1) | KR20070073887A (https=) |
| AP (1) | AP2007003973A0 (https=) |
| AR (1) | AR053415A1 (https=) |
| AU (1) | AU2005293266B2 (https=) |
| BR (1) | BRPI0516340A (https=) |
| CA (1) | CA2583457C (https=) |
| EA (1) | EA013463B1 (https=) |
| IL (1) | IL182444A0 (https=) |
| MX (1) | MX2007004305A (https=) |
| MY (1) | MY142423A (https=) |
| NZ (1) | NZ554515A (https=) |
| TW (1) | TW200614988A (https=) |
| WO (1) | WO2006040625A1 (https=) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| NZ547752A (en) | 2003-11-12 | 2009-12-24 | Phenomix Corp | Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| PL1712547T3 (pl) | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Pochodna bicykloestrowa |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004030502A1 (de) * | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1995237A4 (en) | 2006-03-08 | 2011-07-06 | Kyorin Seiyaku Kk | PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EP2035395A2 (en) | 2006-06-27 | 2009-03-18 | Glenmark Pharmaceuticals S.A. | Novel processes for the preparation of dpp iv inhibitors |
| KR100848491B1 (ko) * | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
| JP2010120851A (ja) * | 2007-02-09 | 2010-06-03 | Kyorin Pharmaceut Co Ltd | 二量化シクロ誘導体 |
| US8143427B2 (en) | 2007-03-22 | 2012-03-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
| UY31290A1 (es) * | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido | |
| PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| US8338450B2 (en) | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
| MX2010007593A (es) * | 2008-01-10 | 2010-10-13 | Sun Pharma Advanced Res Co Ltd | Derivados novedosos de acil cianopirrolidinas. |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CA2732984A1 (en) | 2008-08-07 | 2010-02-11 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
| CN102186474A (zh) * | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | 稳定的医药组合物 |
| UA119131C2 (uk) | 2008-08-15 | 2019-05-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Похідні пурину для застосування при лікуванні пов'язаних із fab захворювань |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| WO2010079433A2 (en) * | 2009-01-07 | 2010-07-15 | Glenmark Pharmaceuticals, S.A. | Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor |
| NZ593361A (en) * | 2009-01-09 | 2012-12-21 | Orchid Res Lab Ltd | Dipeptidyl peptidase iv inhibitors |
| TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
| EP2395988A2 (en) | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| BRPI1008560B1 (pt) | 2009-02-13 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos |
| CN102438617A (zh) | 2009-03-27 | 2012-05-02 | 杏林制药株式会社 | 含有碱性添加剂的基质型缓释制剂 |
| US8748457B2 (en) | 2009-06-18 | 2014-06-10 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| US8614238B2 (en) | 2009-10-19 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| AU2011237775A1 (en) | 2010-04-06 | 2012-11-22 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| EP4055014B1 (en) | 2019-11-06 | 2025-04-30 | Yuhan Corporation | PYRROLIDINE AND PIPERIDINE COMPOUNDS |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54155675A (en) * | 1978-05-30 | 1979-12-07 | Matsushita Electronics Corp | Small-sized fluorescent lamp |
| JPS63299202A (ja) * | 1987-05-29 | 1988-12-06 | Mitsui Mining & Smelting Co Ltd | 磁性金属粉末の表面処理法 |
| JPS6422853A (en) * | 1987-07-17 | 1989-01-25 | Asahi Glass Co Ltd | Nucleoside analog |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| JP3287680B2 (ja) * | 1993-12-03 | 2002-06-04 | 株式会社クラレ | ｃｉｓ−４−アミノ−２−シクロペンテン−１−カルボン酸の製造方法 |
| CZ126598A3 (cs) * | 1995-10-26 | 1998-09-16 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US5952363A (en) * | 1997-03-04 | 1999-09-14 | Novo Nordisk A/S | Pyrrolidine compounds useful in the treatment of diabetes |
| CA2319554C (en) * | 1998-03-31 | 2005-06-28 | Warner-Lambert Company | Quinoxalinones as serine protease inhibitors such as factor xa and thrombin |
| PL343317A1 (en) * | 1998-03-31 | 2001-08-13 | Warner Lambert Co | Benzoxazinones/benzothiazinones as serine protease inhibitors |
| CA2312953A1 (en) * | 1998-03-31 | 1999-10-07 | Warner-Lambert Company | Quinolones as serine protease inhibitors |
| SE9802538D0 (sv) * | 1998-07-13 | 1998-07-13 | Astra Ab | New pharmaceutically active compounds |
| JP2000173537A (ja) * | 1998-09-29 | 2000-06-23 | Toshiba Lighting & Technology Corp | 低圧水銀蒸気放電灯および照明装置 |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| JP2000344722A (ja) * | 1999-06-03 | 2000-12-12 | Kuraray Co Ltd | ４−ヒドロキシメチル−１−アミノシクロペント−２−エン誘導体の製造方法 |
| JP2003518125A (ja) * | 1999-12-22 | 2003-06-03 | イーライ・リリー・アンド・カンパニー | Ｍｒｐ１を阻害する方法および化合物 |
| AU2001228309A1 (en) * | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| US20020057059A1 (en) * | 2000-07-28 | 2002-05-16 | Kazuhisa Ogishi | Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus |
| US7138397B2 (en) | 2000-10-06 | 2006-11-21 | Tanabe Seiyaku Co., Ltd. | Nitrogenous 5-membered ring compounds |
| JP4329291B2 (ja) * | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 含窒素五員環化合物 |
| JP4329290B2 (ja) * | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 脂肪族含窒素五員環化合物 |
| WO2002032885A1 (en) * | 2000-10-18 | 2002-04-25 | Kuraray Co., Ltd. | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0]oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| WO2002051836A1 (en) * | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| JP2002255914A (ja) * | 2001-02-27 | 2002-09-11 | Kuraray Co Ltd | シス−４−アミノ−２−シクロペンテンカルボン酸鉱酸塩の製造方法 |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2296979T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
| DE60221983T2 (de) | 2001-06-27 | 2008-05-15 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| BR0308816A (pt) | 2002-04-08 | 2005-03-22 | Torrent Pharmaceuticals Ltd | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas |
| JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼｉｖ阻害剤 |
| US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| ATE368647T1 (de) | 2002-09-19 | 2007-08-15 | Abbott Lab | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) |
| JP2006522109A (ja) * | 2003-03-31 | 2006-09-28 | 大正製薬株式会社 | 新規なキナゾリン誘導体及びそれらの使用に関連する治療方法 |
| US20050197350A1 (en) | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| EP1627870A1 (en) | 2003-05-15 | 2006-02-22 | Taisho Pharmaceutical Co., Ltd | Cyanofluoropyrrolidine derivative |
| WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| US7230002B2 (en) * | 2004-02-03 | 2007-06-12 | Glenmark Pharmaceuticals Ltd. | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof |
| WO2005075426A1 (en) * | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
-
2005
- 2005-07-26 BR BRPI0516340-4A patent/BRPI0516340A/pt not_active IP Right Cessation
- 2005-07-26 CA CA2583457A patent/CA2583457C/en not_active Expired - Fee Related
- 2005-07-26 NZ NZ554515A patent/NZ554515A/en not_active IP Right Cessation
- 2005-07-26 JP JP2007536276A patent/JP4959569B2/ja not_active Expired - Fee Related
- 2005-07-26 KR KR1020077010262A patent/KR20070073887A/ko not_active Ceased
- 2005-07-26 AU AU2005293266A patent/AU2005293266B2/en not_active Ceased
- 2005-07-26 EP EP05784869.9A patent/EP1799639B1/en not_active Expired - Lifetime
- 2005-07-26 EA EA200700720A patent/EA013463B1/ru not_active IP Right Cessation
- 2005-07-26 WO PCT/IB2005/002204 patent/WO2006040625A1/en not_active Ceased
- 2005-07-26 AP AP2007003973A patent/AP2007003973A0/xx unknown
- 2005-07-26 MX MX2007004305A patent/MX2007004305A/es active IP Right Grant
- 2005-09-29 TW TW094134070A patent/TW200614988A/zh unknown
- 2005-10-03 MY MYPI20054654A patent/MY142423A/en unknown
- 2005-10-12 AR ARP050104282A patent/AR053415A1/es unknown
- 2005-10-12 US US11/250,195 patent/US7205323B2/en not_active Expired - Lifetime
-
2007
- 2007-02-15 US US11/675,180 patent/US7538128B2/en not_active Expired - Lifetime
- 2007-02-15 US US11/675,157 patent/US7524844B2/en not_active Expired - Lifetime
- 2007-04-10 IL IL182444A patent/IL182444A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515962A5 (https=) | ||
| JP4959569B2 (ja) | 新規なジペプチジルペプチダーゼｉｖ阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス | |
| JP3628946B2 (ja) | トリアゾール及びイミダゾール誘導体 | |
| EP0721455B1 (fr) | Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a | |
| AU672802B2 (en) | Imidazole, triazole and tetrazole derivatives | |
| RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
| AU2007316605B2 (en) | 1,2,4-triazole derivatives as sigma receptor inhibitors | |
| AU2008311974B2 (en) | Calcium receptor modulating agents | |
| CN102395567A (zh) | 在治疗糖尿病和肥胖症中用作的tgr5激动剂的三唑和咪唑衍生物 | |
| JP2000502683A (ja) | 新規合成 | |
| JP2011500679A5 (https=) | ||
| JPWO2020262603A5 (https=) | ||
| TW200424197A (en) | Azole compounds | |
| WO2009095394A1 (en) | Diazepanes as histamine h3 receptor antagonists | |
| CN1768053A (zh) | 吡唑化合物 | |
| TW200538442A (en) | Novel imidazoles | |
| NZ593361A (en) | Dipeptidyl peptidase iv inhibitors | |
| US20080227974A1 (en) | Novel Substituted Azetidinones | |
| CN101087757A (zh) | 新的二肽基肽酶ⅳ抑制剂、含有它们的药用组合物及其制备方法 | |
| CN1234032A (zh) | 新的2,4－二氧代吡咯烷和2,4－二氧代四氢呋喃衍生物以及含有它们作为活性成分的药物 | |
| JPWO2020070088A5 (https=) | ||
| JP2011518220A (ja) | Ｃｂ−１リガンドとしての１，５−ジフェニル−ピロリジン−２−オン化合物 | |
| WO2007042910A1 (en) | Imidazoles and their use as hmg-coa reductase inhibitors | |
| CZ20002646A3 (cs) | Deriváty triazolu a imidazolu, způsob jejich přípravy, jejich použití a farmaceutický prostředek, který je obsahuje |